Autopsy report · NCT04750239

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

“Study terminated due to business priorities”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 8 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Y-mAbs Therapeutics

Sponsor type

Industry

Conditions

SCLC

Interventions

Nivatrotamab

Participants

3

Sites

7

Countries

United States

Trials that died the same way

• A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
  “Study terminated due to business decision” (92% match in meaning)
• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
  “Study terminated due to business and strategic decision” (92% match in meaning)
• Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
  “Study terminated for business reasons” (91% match in meaning)
• TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  “Study terminated for strategic business reasons” (90% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.